



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SEP 21 1994

Edward T. Lentz  
Corporate Patents U.S. - UW2220  
SmithKline Beecham Corporation  
P.O. Box 1539  
King of Prussia, PA 19406 - 0939

Re: Patent Term Extension  
Application for  
U.S. Patent No. 4,721,723

Dear Mr. Lentz:

A certificate under 35 USC § 156 is enclosed extending the term of U.S. Patent No. 4,721,723 for a period of 702 days.

Gerald A. Dost  
Special Program Examiner  
Office of Special Programs  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

(703) 305-9282

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 11-44  
Rockville, MD 20857

RE: Paxil

FDA Docket No.: 93E - 0146

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

PATENT NO.: 4,721,723  
DATED: January 26, 1988  
INVENTORS: Roger D. Barnes et al.  
PATENT OWNER: Beecham Group p.l.c.

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

702 DAYS

with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark  
Office to be affixed this 20th day of September 1994.

*Bruce A. Lehman*

Bruce A. Lehman  
Assistant Secretary of Commerce and  
Commissioner of Patents and Trademarks